CGC Meeting

The 8TH Annual CGC Meeting will be held in Denver, CO on August 7th through 9th, 2017.
The CGC annual meeting is a unique forum for education and discussion of best practices in laboratory genomics. The CGC is committed to advancing clinical diagnostics through the use of genomic technologies (microarray, massively parallel sequencing, etc.) and improving the data processing that accompanies these technologies. Our meeting brings together laboratorians, clinicians and researchers with a shared interest in early adoption, performance and interpretation of leading edge technology for cancer and constitutional genomics. Valuable practical aspects of the meetings derive from workshops, expert-panels and round-table discussions on topics relevant for clinical practice, including data interpretation, access to shared resources and best practices in reporting and follow-up. Attendees are encouraged to take an active role in CGC initiatives by joining committees and working groups engaged in developing guidelines and resources for clinical testing.
Come learn from colleagues and offer your experience to others in an informal, engaging setting while enjoying beautiful Denver in August. Click here for more information and registration details.


• Clinical Applications of Microarray and Next Generation Sequencing in Oncology
• Using Multi-Modal Genetic Testing To Optimize Cancer Treatment/Survival
• Challenges to Delivering on the Promise of Personalized Medicine in Cancer Care
• Validation and Quality Control of Arrays and Next Generation Sequencing(including Cell-Free DNA analysis)
• Clinical Interpretation of Sequence and Copy Number Variants/CN-LOH
• Bioinformatics, Clinical Pipelines, Databases, Data Sharing Towards Publication
• Constitutional Arrays and Whole Exome Sequencing; New Technologies
• Creating Practice Guidelines
• Challenging/Teaching Cases
• Billing, Reimbursement, Laboratory Advocacy
… with extensive networking opportunities.
Update: The schedule for the 2017 Annual Meeting has now been finalized!
Click here for more information >>


Dr. Gordan B. MillsDR. GORDAN B. MILLS, M.D., Ph.D.
University of Texas - MD Anderson Cancer Center
Gordon B. Mills, MD, PhD, was recruited to The University of Texas M. D. Anderson Cancer Center (MDACC) in 1994, where he holds the rank of Professor with joint appointments in Systems Biology, Breast Medical Oncology and Immunology, and serves as chairman of the Department of Systems Biology. Dr. Mills is Director of the Kleberg Center for Molecular Markers and Director for the South Campus Research Building II
Click here to continue reading >>

Dr. Mills is also co-Director of the Sheikh Zayed bin Sultan Al Nahyan Institute for Personalized Cancer Therapy. The Center and the Institute are responsible for developing and implementing personalized molecular medicine at MDACC. Dr. Mills has published extensively on the molecular analysis of cancer and currently serves as principal investigator or project investigator on many national peer review grants including Stand Up To Cancer, NIH/NCI SPOREs U24 and PPGs, Department of Defense, CPRIT and Komen Foundation grants, and is a collaborator on multiple other national grants. He has recently been awarded the Komen Brinker award for Scientific Excellence and the Stand up to Cancer Laura Ziskin Prize for mentoring.

Dr. Mills has published more than 700 papers; holds more than 20 patents related to novel technologies and molecular markers and has co-founded an early diagnostics company. He currently sits on the scientific advisory boards of multiple companies and venture capital groups.

Dr. David SpigelDR. DAVID SPIGEL, M.D.
Sarah Cannon Research Institute
Dr. Spigel is the Chief Scientific Officer, Director of the Lung Cancer Research Program and Principal Investigator of the Sarah Cannon Research Institute.
Dr.Spigel joined Sarah Cannon in 2003 and as chief scientific officer, he oversees all scientific aspects of Sarah Cannon's clinical trial program, working with the research physician leaders to ensure the best new agents and studies are available to patients. He serves as a primary contact for the Pharma and biotech partners as well as the strategic site physicians with whom Sarah Cannon conducts cancer research.
Click here to continue reading >>

Dr. Spigel received his bachelor’s degree from Tulane University in New Orleans in 1992, and his medical degree from The University of Tennessee in Memphis in 1996. After completing an internal medicine residency as chief resident at Indiana University Medical Center, he completed a fellowship in hematology and oncology at The Dana-Farber Cancer Institute in Boston. He is board certified in medical oncology. Additionally, he is an associate with Tennessee Oncology, PLLC.

University of Utah
Dr. Raetz received her medical degree and completed her residency training at the University of Wisconsin. She completed a fellowship in Pediatric Hematology-Oncology at the University of Utah and was a member of the faculty from 1998 to 2002. Dr. Raetz returned to the faculty of the University of Utah in 2014, where she is a Professor in the Division of Pediatric Hematology-Oncology. She is board-certified in Pediatric Hematology-Oncology.
Click here to continue reading >>

Dr. Raetz’s clinical interests include the treatment of all pediatric cancers and hematologic disorders, with an emphasis on acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma. Over the past 12 years, she has been an active member of the Children’s Oncology Group (COG), serving as study chair for ALL clinical and biology clinical trials. Currently she is a member of the COG ALL Executive Committee, the ALL liaison for the Adolescent and Young Adult Discipline Committee, a member of the Hematology-Oncology Steering Committee and a Vice Chair for the ALL Disease Committee, overseeing frontline clinical trials.

Dr. Raetz returned to the University of Utah Department of Pediatrics and Huntsman Cancer Institute (HCI) in January of 2014 to serve as the Medical Director for a newly established High Risk Leukemia and Lymphoma Program at Primary Children’s Hospital, to continue research in childhood leukemia, and to serve as Chair of the Data and Safety Monitoring Committee at HCI. Dr. Raetz also participates in the HCI Experimental Therapeutics program.


Are you a trainee or technologist? Travel awards available for exceptional abstracts! Click here for more information.


The CGC Annual Meeting offers numerous opportunities for industry and academic partners to market and advertise their products and services. Through a series of scheduled networking sessions sponsors can connect with participants from major diagnostic laboratories across North America. For more information regarding sponsorship and advertising opportunities, click here. Sponsorship commitment forms can be found here.

Comments are closed.